<code id='16B4D702AC'></code><style id='16B4D702AC'></style>
    • <acronym id='16B4D702AC'></acronym>
      <center id='16B4D702AC'><center id='16B4D702AC'><tfoot id='16B4D702AC'></tfoot></center><abbr id='16B4D702AC'><dir id='16B4D702AC'><tfoot id='16B4D702AC'></tfoot><noframes id='16B4D702AC'>

    • <optgroup id='16B4D702AC'><strike id='16B4D702AC'><sup id='16B4D702AC'></sup></strike><code id='16B4D702AC'></code></optgroup>
        1. <b id='16B4D702AC'><label id='16B4D702AC'><select id='16B4D702AC'><dt id='16B4D702AC'><span id='16B4D702AC'></span></dt></select></label></b><u id='16B4D702AC'></u>
          <i id='16B4D702AC'><strike id='16B4D702AC'><tt id='16B4D702AC'><pre id='16B4D702AC'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:fashion    Page View:2744

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In